COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

October 9, 2025 updated by: Regeneron Pharmaceuticals

A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

The primary objectives of the study are:

  • To evaluate the extent of effect, if any, of REGN10933+REGN10987 administration on vaccine-induced neutralizing antibody responses to SARS-CoV-2 by Moderna mRNA-1273
  • To evaluate the time interval required between REGN10933+REGN10987 administration and Moderna mRNA-1273 vaccination, to ensure no meaningful impact on vaccine-induced neutralizing antibody responses to SARS-CoV-2

The secondary objectives of the study are:

  • To quantify the alteration of antigen specificity of vaccine-induced SARS-CoV-2 antibody responses when administered with different dose regimens of REGN10933+REGN10987
  • To evaluate the safety and tolerability of REGN10933+REGN10987 and Moderna mRNA-1273 vaccine when administered in close succession
  • To assess the concentrations of REGN10933 and REGN10987 in serum over time in participants who receive REGN10933+REGN10987 and Moderna mRNA-1273 vaccine
  • To evaluate the immunogenicity of REGN10933 and REGN10987 over time

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
295

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72211
        • Regeneron Research Site
      • Rogers, Arkansas, United States, 72758
        • Regeneron Research Site
    • Florida
      • Hialeah, Florida, United States, 33012
        • Regeneron Research Site
      • Miami, Florida, United States, 33186
        • Regeneron Research Site
      • Orlando, Florida, United States, 32789
        • Regeneron Research Site
    • Ohio
      • Dayton, Ohio, United States, 45417
        • Regeneron Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Key Inclusion Criteria:

  1. Healthy or has chronic medical condition(s) that are stable and well-controlled in the opinion of the investigator and that are not likely to require significant medical intervention through the end of study
  2. Willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to SARS-CoV-2 infection and transmission

Key Exclusion Criteria:

  1. Positive RT-PCR test result for SARS-CoV-2 infection at screening or baseline
  2. Positive serology test result for anti-SARS-CoV-2 antibodies at screening or baseline
  3. COVID-19 diagnosis, positive SARS-CoV-2 infection, or positive SARS-CoV-2 serology at any time prior to screening
  4. Previously received an investigational, authorized, or approved coronavirus vaccine (eg, SARS-CoV-2 vaccine, MERS-CoV vaccine)
  5. Currently enrolled in, or has plans to enroll in, any interventional study to prevent or treat COVID-19
  6. Received investigational or approved passive antibodies for SARS-CoV-2 infection prophylaxis ad defined in the protocol
  7. Received intravenous immunoglobulin (IVIG) or blood products in the last 3 months
  8. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by study participation
  9. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator, that may confound the results of the study or pose an additional risk to the subject by study participation
  10. Medically attended acute illness or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening
  11. Clinical history of myocarditis and/or pericarditis

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Wave 1 Dose 1
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 1 Dose 2
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 1 Dose 3
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 1 Vaccine only
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 2 Dose 1
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 2 Dose 2
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 2 Vaccine only
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 3 Dose 1
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 3 Dose 2
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 3 Vaccine only
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 4 Dose 1
Drug: casirivimab+imdevimab
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Other Names:
  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933
  • REGN10987
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection
Experimental: Wave 4 Vaccine only
Biological: Moderna mRNA-1273 vaccine
Single intramuscular (IM) injection

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)
Time Frame: 56 days after first dose of vaccine
High dose - (1200 mg arms)
56 days after first dose of vaccine
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg)
Time Frame: 56 days after first dose of vaccine
Submaximal dose - (150 mg, 300 mg, 600 mg, 48 mg, and 12 mg)
56 days after first dose of vaccine

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Time Frame: Up to 365 Days from 1st dose of Vaccination
Anti-S1-RBD protein
Up to 365 Days from 1st dose of Vaccination
Median Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Time Frame: Up to 365 Days from 1st dose of Vaccination
Anti-S1-RBD protein. Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Up to 365 Days from 1st dose of Vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Time Frame: Up to 365 Days from 1st dose of Vaccination
Anti-S1-RBD protein. Relative difference is calculated as: [(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm] x 100%
Up to 365 Days from 1st dose of Vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Time Frame: Up to 365 Days from 1st dose of Vaccination
- Anti-S protein (Spike protein)
Up to 365 Days from 1st dose of Vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Time Frame: Up to 365 Days from 1st dose of Vaccination
Anti-S protein Relative difference is calculated as: [(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm] x 100%
Up to 365 Days from 1st dose of Vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein
Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein (Spike) Relative difference is calculated as: [(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm] x 100%
Up to 365 Days from 1st dose of vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S1-RBD
Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S1-RBD protein Relative difference is calculated as: [(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm] x 100%
Up to 365 Days from 1st dose of vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S1-RBD
Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S1-RBD protein Relative difference is calculated as: [(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm] x 100%
Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Up to 365 Days from 1st dose of vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein (Spike protein)
Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein (Spike protein) Relative difference is calculated as: [(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm] x 100%
Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Time Frame: Up to 365 Days from 1st dose of vaccination
Anti-S protein (Spike protein) Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Up to 365 Days from 1st dose of vaccination
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to SARS-CoV-2 S Protein Assessed Over Time After the First Dose of Moderna mRNA-1273 Vaccine
Time Frame: Up to 365 Days from 1st dose of vaccination
Up to 365 Days from 1st dose of vaccination
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study
Time Frame: Up to 401 Days
Up to 401 Days
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study
Time Frame: Up to 401 Days
Up to 401 Days
Number of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987
Time Frame: Through Day 4 post-infusion
Through Day 4 post-infusion
Number of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987
Time Frame: Through Day 4 post-infusion
Through Day 4 post-infusion
Number of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine
Time Frame: Through Day 4 post-infusion
Through Day 4 post-infusion
Number of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine
Time Frame: Through Day 29 post-infusion or post-injection
Grade 2 - characterized by an adverse local or general response from exposure and oral intervention indicated Grade 3 - hospitalization indicated and intravenous response required Grade 4 - Life Threatening consequence and urgent intervention indicated Grade 5 - Death
Through Day 29 post-infusion or post-injection
Concentrations of REGN10933 in Serum Over Time
Time Frame: Up to 182 Days
Up to 182 Days
Concentrations of REGN10987 in Serum Over Time
Time Frame: Up to 182 Days
Up to 182 Days
Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10987
Time Frame: Up to Day 183
Up to Day 183
Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10933
Time Frame: Up to Day 183
Up to Day 183
Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10987
Time Frame: Up to Day 183
Up to Day 183
Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10933
Time Frame: Up to Day 183
Up to Day 183

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Regeneron Pharmaceuticals

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 29, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 21, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 21, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 19, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 19, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 21, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 20, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 9, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • R10933-10987-COV-2118

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD Sharing Time Frame

When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

IPD Sharing Access Criteria

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings